In stable MS patients, stopping Ocrevus does not seem to increase the risk of disease activity or disability progression for ...

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Multiple sclerosis (MS) is a debilitating autoimmune disease of the brain and spinal cord. The disease can affect everyone differently, but depending on the progression and severity of the disease, ...

A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

Significantly higher levels of HRQoL were reported in patients who lived in cities, had lower MS severity and fatigue, had higher cognitive processing speed, and had achieved higher educational ...